The rise of PAMPA

Expert Opinion on Drug Metabolism and Toxicology

Volumn 1, Issue 2, 2005, Pages 325-342

  Avdeef, Alex ^a  

^a PION INC   (United States)

Author keywords

Caco 2; flux pKa; gradient pH; human intestinal absorption; PAMPA

Indexed keywords

DRUG;

ARTIFICIAL MEMBRANE; BIOLOGICAL MODEL; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECT; ECONOMICS; HUMAN; INTESTINE ABSORPTION; LIPID BILAYER; METABOLISM; METHODOLOGY; PH; PHARMACEUTICS; PHYSIOLOGY; REVIEW;

CELL MEMBRANE PERMEABILITY; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; LIPID BILAYERS; MEMBRANES, ARTIFICIAL; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33644895842     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.1.2.325     Document Type: Review

References (82)

1. DRESSMAN JB, AMIDON GL, FLEISHER D: Absorption potential: estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci. (1985) 74:588-589.
2. BALON K, MUELLER BW, RIEBESEHL BU: Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm. Res. (1999) 16:882-888. (Pubitemid 29284200)
3. AMIDON GL, LENNERNÄS H, SHAH VP, CRISON JR: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. (1995) 12:413-420.
4. FDA: Guidance for Industry, Waiver of In vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. FDA, Washington, DC, USA (2000).
5. RINAKI E, VALSAMI G, MACHERAS P: Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm. Res. (2003) 20:1917-1925. (Pubitemid 38005521)
6. BERGSTRÖM CAS, STRAFFORD M, LAZAROVA L, AVDEEF A, LUTHMAN K, ARTURSSON P: Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. (2003) 46:558-570. (Pubitemid 36182757)
7. JOHNSON K, SWINDELL A: Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm. Res. (1996) 13:1795-1798. (Pubitemid 27034109)
8. CURATOLO W: Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Tech. Today (1998) 1:387-393. (Pubitemid 28559133)
9. AVDEEF A: Absorption and Drug Development. Wiley-Intercience, New York, USA (2003):116-246.
10. KARLSSON J, ARTURSSON P: A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelial (Caco-2) cells grown in permeable filter chambers. Int. J. Pharm. (1991) 71:55-64.
11. ADSON A, BURTON PS, RAUB TJ, BARSUHN CL, AUDUS KL, HO NFH: Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J. Pharm. Sci. (1995) 84:1197-1204.
12. ARTURSSON P: Application of physicochemical properties of molecules to predict intestinal permeability. AAPS Workshop on Permeability Definitions and Regulatory Standards. Arlington, VA, USA (1998).
13. YAMASHITA S, FURUBAYASHI T, KATAOKA M, SAKANE T, SEZAKI H, TOKUDA H: Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur. J. Pharm. Sci. (2000) 10:195-204. (Pubitemid 30190095)
14. HO NFH, RAUB TJ, BURTON PS et al.: Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers. In:Transport Processes in Pharmaceutical Systems. GL Amidon, PI Lee, EM Topp (Eds). Marcel Dekker, New York, USA (2000):219-316.
15. KANSY M, SENNER F, GUBERNATOR K: Physicochemical high throughput screening: parallel artificial membrane permeability assay in the description of passive absorption processes. J. Med. Chem. (1998) 41:1007-1010. (Pubitemid 28207375)
16. AVDEEF A, ARTURSSON P, NEUHOFF S, LAZAROVA L, GRSJÖ J, TAVELIN S: Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA pKa flux method. Eur. J. Pharm. Sci. (2005) (in press).
17. AVDEEF A, STRAFFORD M, BLOCK E, BALOGH MP, CHAMBLISS W, KHAN I: Drug absorption in vitro model: filterimmobilized artificial membranes. 2. Studies of the permeability properties of lactones in piper methysticum forst. Eur. J. Pharm. Sci. (2001) 14:271-280. (Pubitemid 33001619)
18. KANSY M, FISCHER H, KRATZAT K, SENNER F, WAGNER B, PARRILLA I: High-throughput aritificial membrane permeability studies in early lead discovery and development. In:Pharmacokinetic Optimization in Drug Research. B Testa, H van de Waterbeemd, G Folkers, R Guy (Eds), Verlag Helvetica Chimica Acta, ZÜrich and Wiley - VCH, Weinheim, Germany (2001):447-464.
19. AVDEEF A: High-throughput measurements of solubility profiles. In:Pharmacokinetic Optimization in Drug Research. B Testa, H van de Waterbeemd, G Folkers, R Guy (Eds), Verlag Helvetica Chimica Acta, ZÜrich and Wiley - VCH, Weinheim, Germany (2001):305-326.
20. FALLER B, WOHNSLAND F: Physicochemical parameters as tools in drug discovery and lead optimization. In:Pharmacokinetic Optimization in Drug Research. B Testa, H van de Waterbeemd, G Folkers, R Guy (Eds), Verlag Helvetica Chimica Acta, ZÜrich and Wiley - VCH, Weinheim, Germany (2001):257-274.
21. SUGANO K, HAMADA H, MACHIDA M, USHIO H, SAITOH K, TERADA K: Optimized conditions of biomimetic artificial membrane permeability assay. Int. J. Pharm. (2001) 228:181-188. (Pubitemid 32905377)
22. SUGANO K, HAMADA H, MACHIDA M, USHIO H: High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeability assay. J. Biomolec. Screen. (2001) 6:189-196. (Pubitemid 32554136)
23. WOHNSLAND F, FALLER B: Highthroughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J. Med. Chem. (2001) 44:923-930. (Pubitemid 32861617)
24. SUGANO K, TAKATA N, MACHIDA M, SAITOH K, TERADA K: Prediction of passive intestinal absorption using biomimetic artificial membrane permeation assay and the paracellular pathway model. Int. J. Pharm. (2002) 241:241-251. (Pubitemid 34718026)
25. ZHU C, JIANG L, CHEN T-M, HWANG K-K: A comparative study of artificial membrane permeability assay for high-throughput profiling of drug absorption potential. Eur. J. Med. Chem. (2002) 37:399-407. (Pubitemid 34465549)
26. VEBER DF, JOHNSON SR, CHENG H-Y, SMITH BR, WARD KW, KOPPLE KD: Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. (2002) 45:2615-2623. (Pubitemid 34595232)
27. LEVIN JI, DU TM: Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme. Drug Des. Discov. (2003) 18:123-126. (Pubitemid 39157465)
28. DI L, KERNS EH, FAN K, MCCONNELL OJ, CARTER GT: High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. (2003) 38 223-232. (Pubitemid 36349665)
29. SUGANO K, NABUCHI Y, MACHIDA M, ASO Y: Prediction of human intestinal permeability using artificial membrane permeability. Int. J. Pharm. (2003) 257:245-251. (Pubitemid 36507050)
30. HWANG KK, MARTIN NE, JIANG L, ZHU C: Permeation prediction of M100240 using the parallel artificial membrane permeability assay. J. Pharm. Pharmaceut. Sci. (2003) 6:315-320. (Pubitemid 38097544)
31. RUELL JA, TSINMAN KL, AVDEEF A: PAMPA - a drug absorption in vitro model.
32. Unstirred water layer in iso-pH mapping assays and pKaflux - optimized design (pOD-PAMPA). Eur. J. Pharm. Sci. (2003) 20:393-402.
33. LIU H, SABUS C, CARTER GT, DU C, AVDEEF A, TISCHLER M: Solubilizer selection in the parallel artificial membrane permeability assay (PAMPA) for in vitro permeability measurement of low solubility compounds. Pharm. Res. (2003) 20:1820-1826.
34. NIELSEN P, AVDEEF A: PAMPA - a drug absorption in vitro model. 8. Apparent filter porosity and the unstirred water layer. Eur. J. Pharm. Sci. (2004) 22:33-41. (Pubitemid 38543012)
35. OBATA K, SUGANO K, MACHIDA M, ASO Y: Biopharmaceuitics classification by high throughput solubility assay and PAMPA. Drug Dev. Ind. Pharm. (2004) 30:181-185. (Pubitemid 38420262)
36. HUQUE FTT, BOX K, PLATTS JA, COMER J: Permeability through DOPC/ dodecane membranes: measurement and LFER modelling. Eur. J. Pharm. Sci. (2004) 23:223-232. (Pubitemid 39369877)
37. ANO R, KIMURA Y, SHIMA M, MATSUNO R, UENO T, AKAMATSU M: Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. (2004) 12:257-264. (Pubitemid 38096238)
38. AVDEEF A, NIELSEN PE, TSINMAN O: PAMPA - a drug absorption in vitro model.
39. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates. Eur. J. Pharm. Sci. (2004) 22:365-374.
40. BERMEJO M, AVDEEF A, RUIZ A et al.: PAMPA - a drug absorption in vitro model.
41. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. (2004) 21:429-441.
42. RUELL JA, TSINMAN O, AVDEEF A: Acid-base cosolvent method for determining aqueous permeability of amiodarone, itraconazole, tamoxifen, terfenadine and other very insoluble molecules. Chem. Pharm. Bull. (2004) 52:561-565. (Pubitemid 41701905)
43. MIRET S, ABRAHAMS L, DE GOENE EM: Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa. J. Biomed. Screen. (2004) 9:598-606.
44. SAITOH R, SUGANO K, TAKATA N et al.: Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed in humans. Pharm. Res. (2004) 21:749-755. (Pubitemid 39011295)
45. KERNS EH, DI L, PETUSKY S, FARRIS M, LEY R, JUPP P: Combined application of parallel membrane permeability assay and Caco-2 permeability assays in drug discovery. J. Pharm. Sci. (2004) 93:1440-1453. (Pubitemid 38725018)
46. CARON G, ERMONDI G, DAMIANO A et al.: Ionization, lipophilicity, and molecular modeling to investigate permeability and other biological properties of amlodipine. Bioorg. Med. Chem. (2004) 23:6107-6118. (Pubitemid 39440451)
47. ABDICHE YN, MYSZKA DG: Probing the mechanism of drug/lipid membrane interactions using Biacore. Anal. Biochem. (2004) 328:233-243. (Pubitemid 38542942)
48. NAGAHARA N, TAVELIN S, ARTURSSON P: The contribution of the paracellular route to pH dependent permeability of ionizable drugs. J. Pharm Sci. (2004) 93:2972-2984. (Pubitemid 39657801)
49. MATSSON P, BERGSTRÖM CA, NAGAHARA N, TAVELIN S, NORINDER U, ARTURSSON P: Exploring the role of different drug transport routes in permeability screening. J. Med. Chem. (2005) (in press).
50. AVDEEF A, TSINMAN O: PAMPA - a drug absorption in vitro model. 13. Chemical selectivity due to membrane hydrogen bonding: in combo comparisons of HDM-, DOPC- and DS-PAMPA models. Eur. J. Pharm. Sci. (2005) submitted.
51. AVDEEF A: Physicochemical profiling (solubility, permeability, and charge state). Curr. Topics Med. Chem. (2001) 1:277-351.
52. KERNS EH: High throughput physicochemical profiling for drug discovery. J. Pharm. Sci. (2001) 90:1838-1858. (Pubitemid 33062605)
53. LIPINSKI CA: Observation on current ADMET technology: no uniformity exists. Annual Meeting of the Society of Biomolecular Screening. The Hauge, The Netherlands (2002).
54. KERNS EH, DI L: Multivariate pharmaceutical profiling for drug discovery. Curr. Top. Med. Chem. (2002) 2:87-98.
55. KARIV I, ROURICK RA, KASSEL DB, CHUNG TD: Improvement of hit-to-lead optimization by integration of in vitro HTS experimental models for early determination of pharmacokinetic properties. Comb. Chem. High Throughput Screen. (2002) 5:459-472. (Pubitemid 35439595)
56. AVDEEF A: High-throughput measurements of permeability profiles. In:Drug Bioavailability. Estimation of Solubility, Permeability, Absorption and Bioavailability. H van de Waterbeemd, H LennernÄs, P Artursson (Eds). Wiley - VCH: Weinheim, Germany (2003):46-70.
57. RUELL J: Membrane-based drug assays. Mod. Drug Disc. (2003):28-30.
58. KERNS EH, DI L: Pharmaceutical profiling in drug discovery. Drug Disc. Today (2003) 8:316-323. (Pubitemid 36332223)
59. DI L, KERNS EH: Profiling drug-like properties in discovery research. Curr. Opin. Chem. Biol. (2003) 7:402-408. (Pubitemid 36782368)
60. YOUDIM KA, AVDEEF A, ABBOTT NJ: In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Disc. Today (2003) 8:997-1003. (Pubitemid 37468418)
61. AVDEEF A, TESTA B: Physicochemical profiling in drug research: a brief state-ofthe- art of experimental techniques. Cell. Molec. Life Sci. (2003) 59:1681-1689. (Pubitemid 35346972)
62. RUELL JA, AVDEEF A: Absorption using the PAMPA Approach. In:Optimization in Drug Discovery: In vitro Methods. Z Yan, GW Caldwell (Eds), The Humana Press, Totowa, NJ, USA (2004):37-64.
63. KANSY M, FISCHER H, BENDELS S et al.: Physicochemical methods for estimating permeability and related properties. In:Pharmaceutical Profiling in Drug Discovery for Lead Selection. RT Borchardt, EH Kerns, CA Lipinski, DR Thakker, B Wang (Eds), AAPS Press, Arlington, VA, USA (2004):197-216.
64. FALLER B: High-throughput physicochemical profiling: potential and limitations. In: Analysis and Purification Methods in Combinatorial Chemistry. Wiley & Sons, Inc, New York, USA (2004) (in press).
65. KANSY M, AVDEEF A, FISCHER H: Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. Drug Discov. Today: Technologies (2005) (in press).
66. AVDEEF A: HT solubility and permeability: MAD-PAMPA analysis. In:Physicochemical and Biological Profiling in Drug Research. SD KrÄmer, G Folkers, B Testa (Eds), Wiley-VCH, Weinheim, Germany (2005) (in press).
67. RUELL J, AVDEEF A: A meaured solution. Mod. Drug Disc. (2003):47-49.
68. PARTRIDGE WM: Peptide Drug Delivery to the Brain. Raven Press, New York, USA (1991):52-88.
69. GUTKNECHT J, TOSTESON DC: Diffusion of weak acids across lipid membranes: effects of chemical reactions in the unstirred layers. Science (1973) 182:1258-1261.
70. WALTER A, GUTKNECHT J: Monocarboxylic acid permeation through lipid bilayer membranes. J. Mem. Biol. (1984) 77:255-264. (Pubitemid 14187170)
71. ANTONENKO YN, DENISOV GA, POHL P: Weak acid transport across bilayer lipid membrane in the presence of buffers. Biophys. J. (1993) 64:1701-1710.
72. XIANG T-X, ANDERSON BD: Diffusion of ionizable solutes across planar lipid bilayer membranes: boundary-layer pH gradients and the effect of buffers. Pharm. Res. (1993) 10:1654-1661. (Pubitemid 23325672)
73. LENNERNÄS H: Human intestinal permeability. J. Pharm. Sci. (1998) 87:403-410. (Pubitemid 28175799)
74. VAN DE WATERBEEMD H: Propertybased optimization. In:Physicochemical and Biological Profiling in Drug Research. SD KrÄmer, G Folkers, B Testa (Eds), Wiley-VCH, Weinheim, Germany (2005) (in press).
75. ABRAHAM M H: Scales of hydrogen bonding - their construction and application to physicochemical and biochemical processes. Chem. Soc. Revs. (1993) 22:73-83.
76. ABRAHAM MH, IBRAHIM A, ZISSIMOS AM, ZHAO YH, COMER J, REYNOLDS DP: Application of hydrogen bonding calculations in property based drug design. Drug Disc. Today (2002) 7:1056-1063.
77. JAPERTAS P, DIDZIAPETRIS R, PETRAUSKAS A: Fragmental methods in the design of new compounds. Applications of the advanced algorithm builder. Quant. Struct. Activ. Relat. (2002) 21:23-37. (Pubitemid 34619464)
78. ZMUIDINAVICIUS D, DIDZIAPETRIS R, JAPERTAS P, AVDEEF A, PETRAUSKAS A: Classification structure-activity relations (C-SAR) in prediction of human intestinal absorption. J. Pharm. Sci. (2003) 92:621-633. (Pubitemid 36258977)
79. DIDZIAPETRIS R, JAPERTAS P, AVDEEF A, PETRAUSKAS A: Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. (2003) 11:391-406. (Pubitemid 38455825)
80. AVDEEF A: Assessment of distribution - pH profiles. In:Methods and Principles in Medicinal Chemistry, Vol.4. V Pliska, B Testa, H van de Waterbeemd (Eds). VCH Publishers, Weinheim, Germany (1996):109-139.
81. http://www.PAMPA2002.com
82. http://www.ap-algorithms.com